Dr. Getzenberg will lead the clinical development of Veru’s portfolio of drugs under development, including Tamsulosin DRS (Tamsulosin HCl extended release for oral suspension) for the treatment of benign prostatic hyperplasia (BPH), MSS-722 for male infertility, APP-944 for hot flashes in men who are on hormonal therapies for advanced prostate cancer, and APP-111 for prostate, ovarian and breast cancers.
“Robert is eminently qualified to lead our product development efforts,” said
Dr. Getzenberg, most recently served as Therapeutic Area Lead, Prostate Cancer for
Dr. Getzenberg completed his postdoctoral fellowship at the
More information about the
Press Release Kari Sharp